Originally published In Press as doi:10.1074/mcp.M700505-MCP200 on March 24, 2008.
Molecular & Cellular Proteomics 7:1241-1253, 2008.
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
In-cell Selectivity Profiling of Serine Protease Inhibitors by Activity-based Proteomics*,S
Ludovic C. J. Gillet ,
Kenji Namoto ,
Alexandra Ruchti ,
Sjouke Hoving ,
Danielle Boesch ,
Bruno Inverardi ,
Dieter Mueller ,
Michele Coulot¶,
Patrick Schindler¶,
Patrick Schweigler ,
Anna Bernardi and
Shirley Gil-Parrado ,||
From the Center for Proteomic Chemistry/Expertise Platform Proteases, Developmental and Molecular Pathways, and ¶ Biologics Center, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland
Activity-based proteomics is a methodology that is used to quantify the catalytically active subfraction of enzymes present in complex mixtures such as lysates or living cells. To apply this approach for in-cell selectivity profiling of inhibitors of serine proteases, we designed a novel activity-based probe (ABP). This ABP consists of (i) a fluorophosphonate-reactive group, directing the probe toward serine hydrolases or proteases and (ii) an alkyne functionality that can be specifically detected at a later stage with an azide-functionalized reporter group through a Cu(I)-catalyzed coupling reaction ("click chemistry"). This novel ABP was shown to label the active site of several serine proteases with greater efficiency than a previously reported fluorophosphonate probe. More importantly, our probe was cell-permeable and achieved labeling of enzymes within living cells with efficiency similar to that observed for the corresponding lysate fraction. Several endogenous serine hydrolases whose activities were detected upon in-cell labeling were identified by two-dimensional gel and MS analyses. As a proof of principle, cell-permeable inhibitors of an endogenous serine protease (prolyl endopeptidase) were assessed for their potency and specificity in competing for the in situ labeling of the selected enzyme. Altogether these results open new perspectives for safety profiling studies in uncovering potential cellular "side effects" of drugs (unanticipated off-target inhibition or activation) that may be overlooked by standard selectivity profiling methods.
|| To whom correspondence should be addressed: Center for Proteomic Chemistry/Expertise Platform Proteases, Novartis Insts. for BioMedical Research, Fabrikstrasse 16-2.72.2, CH-4002 Basel, Switzerland. Tel.: 41-61-6962485; Fax: 41-61-6968132; E-mail: shirley.gil_parrado{at}novartis.com

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|